US 12,344,664 B2
Antibodies to amyloid beta
Maria Groves, Cambridge (GB); Suzanne Gustavsson, Huddinge (SE); Kina Höglund, Solna (SE); Chris Lloyd, Cambridge (GB); Adrian Nickson, Cambridge (GB); Camilla Niva, Arsta (SE); Sylvia Simon, Stockholm (SE); David Lowne, Cambridge (GB); Fraser Welsh, Cambridge (GB); and Per-Ola Freskgärd, Södertälje (SE)
Assigned to MedImmune Limited, Cambridge (GB)
Filed by MedImmune Limited, Cambridge (GB)
Filed on Mar. 14, 2024, as Appl. No. 18/604,668.
Application 18/604,668 is a continuation of application No. 17/673,449, filed on Feb. 16, 2022, granted, now 12,098,191.
Application 17/673,449 is a continuation of application No. 16/864,439, filed on May 1, 2020, granted, now 11,286,297, issued on Mar. 29, 2022.
Application 16/864,439 is a continuation of application No. 15/793,510, filed on Oct. 25, 2017, granted, now 10,662,239, issued on May 26, 2020.
Application 15/793,510 is a continuation of application No. 14/435,520, granted, now 9,834,598, issued on Dec. 5, 2017, previously published as PCT/EP2013/071567, filed on Oct. 15, 2013.
Claims priority of provisional application 61/713,996, filed on Oct. 15, 2012.
Prior Publication US 2024/0294619 A1, Sep. 5, 2024
Int. Cl. C07K 16/18 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 25/28 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/28 (2018.01); A61K 38/1716 (2013.01); A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/60 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An isolated antibody molecule that is selective for binding human amyloid beta 1-42 peptide (Aβ1-42) over human amyloid beta 1-40 peptide (Aβ1-40); wherein the antibody molecule comprises:
(i) a VH domain comprising the following HCDRs:
HCDR1 SEQ ID NO: 525,
HCDR2 SEQ ID NO: 526, and
HCDR3 SEQ ID NO: 527, and
(ii) a VL domain comprising the following LCDRs:
LCDR1 SEQ ID NO: 534,
LCDR2 SEQ ID NO: 535, and
LCDR3 SEQ ID NO: 536;
and wherein the VL domain has a threonine at the amino acid position corresponding to position 80 of SEQ ID NO: 407.